← Leaderboards
Paul Geeleher
University Of Chicago
$5,367,404
Attributed
$5,367,404
Total exposure
4
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.2M · FY2018–25$2M$1.5M$1M$500K$0
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$5,367,404 · 4
By mechanism
R01$2,360,075 · 1
R35$2,183,749 · 1
R00$738,983 · 1
K99$84,597 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of Chicago
Same institution · by research overlap
- Dezheng Huo$7,892,516
- Tara Olive Henderson$5,271,797
- Karen E Kim$11,883,483
- William L Murphy$10,593,192
- Rong Stephanie Huang$4,360,763
Others in their field
Other Emerging Leaders on “Data Set”
- Joel A Lipkin · Four Points Technology, Llc$182,936,915
- Terry Drinkwine · Carahsoft Technology Corporation$93,011,563
- Leonard Freedman · Leidos Biomedical Research, Inc.$92,966,200
- April Brinkoetter · Hungry Heart Media, Inc.$59,802,265
- Martha Hering · Westat, Inc.$57,098,843
- Susan Abushakra · Alzheon, Inc.$47,265,244
Research focus
Data SetGene ExpressionComputing MethodologiesCellsProgramsTranscriptomicsGenesMalignant NeoplasmsGenetic VariationMolecularExperimental StudyGeneticGenome SequencingGenotypeDrug ScreeningFutureCancer PatientClinically ActionableClinical ResearchCancer GenomeDrug TargetingCell LineCancer Cell LineClinic
Grant awards (14)
Developing new therapeutic strategies for pediatric tumors that lack clinically actionable mutations$479,150
R01 · FY2025 · CA · contact PI
Developing new therapeutic strategies for pediatric tumors that lack clinically actionable mutations$455,194
R01 · FY2024 · CA · contact PI
Computational tools for estimating cell-type-specific effects in bulk RNA-seq and spatial transcriptomics data, using reference single-cell RNA-seq datasets$436,750
R35 · FY2024 · GM · contact PI
Developing new therapeutic strategies for pediatric tumors that lack clinically actionable mutations$469,566
R01 · FY2023 · CA · contact PI
Computational tools for estimating cell-type-specific effects in bulk RNA-seq and spatial transcriptomics data, using reference single-cell RNA-seq datasets$436,750
R35 · FY2023 · GM · contact PI
Developing new therapeutic strategies for pediatric tumors that lack clinically actionable mutations$469,566
R01 · FY2022 · CA · contact PI
Computational tools for estimating cell-type-specific effects in bulk RNA-seq and spatial transcriptomics data, using reference single-cell RNA-seq datasets$436,750
R35 · FY2022 · GM · contact PI
Developing new therapeutic strategies for pediatric tumors that lack clinically actionable mutations$486,599
R01 · FY2021 · CA · contact PI
Computational tools for estimating cell-type-specific effects in bulk RNA-seq and spatial transcriptomics data, using reference single-cell RNA-seq datasets$436,750
R35 · FY2021 · GM · contact PI
Novel computational approaches for pharmacogenomic discovery$243,652
R00 · FY2021 · HG · contact PI
Computational tools for estimating cell-type-specific effects in bulk RNA-seq and spatial transcriptomics data, using reference single-cell RNA-seq datasets$436,749
R35 · FY2020 · GM · contact PI
Novel computational approaches for pharmacogenomic discovery$246,364
R00 · FY2020 · HG · contact PI
Novel computational approaches for pharmacogenomic discovery$248,967
R00 · FY2019 · HG · contact PI
Novel computational approaches for pharmacogenomic discovery$84,597
K99 · FY2018 · HG · contact PI